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Introduction and Objectives: Hepatitis C Virus (HCV) is a blood-borne, hepatotropic RNA virus causing both
acute and chronic infection. Chronic HCV infection predisposes individuals to liver fibrosis, cirrhosis and
hepatocellular carcinoma. Staging of fibrosis prior to treatment to determine either treatment choice or
required follow up, is standard practice. However, this often acts as a barrier to treatment initiation. We
sought to validate the hypothesis that those individuals; mono-infected with HCV, ≤35 years of age; with no
additional hepatic insult were unlikely to have significant fibrosis.
Methods: We performed a retrospective analysis of a Hepatitis C Virus database; with collation of relevant
basic demographics including age, sex and baseline Transient Elastography measurements pre-treatment.
Additionally, we compared the reliability of biochemical fibrosis scores with corresponding transient elastog-
raphy scores.
Results: Our results support the hypothesis that those individuals with chronic HCV ≤35 years old, with no
additional risk for fibrogenesis did not have significant liver fibrosis within our cohort.
Conclusion: Patients ≤35 years old likely do not necessitate fibrosis assessment prior to Direct Acting Antiviral
(DAA) treatment in the absence of other significant risk factors for fibrosis. Given the emerging evidence that
DAA treatment results in a significant decrease in all-cause mortality and hepatocellular carcinoma develop-
ment, treatment of those with chronic HCV represents a global priority.
© 2021 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)Keywords:
Hepatitis C Virus (HCV)
Fibrosis assessment
Transient elastography
Non-invasive fibrosis markersentre for Regenerative Medi-
UU United Kingdom.
1 People who inject drugs (PWID), Hepatitis C Virus (HCV), Hepatocellular Carci-
noma (HCC), United Kingdom (UK), Alanine Transferase (ALT), Aspartate Transferase
(AST), International normalised ratio (INR)
blished by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license1. Introduction
The importance of identification and treatment of hepatitis C pop-
ulations cannot be overstated, given it is a leading cause of liver dis-
ease worldwide [1,2].
According to the World Health Organisation (WHO) global hepati-
tis report [3], there are 71 million people with chronic HCV. Owing to
its inherent viral heterogeneity and frequent mutations; develop-
ment of an HCV vaccine has remained elusive. However highly effec-
tive therapy now opens the possibility cure for all from HCV if the
therapy can be delivered.
In the UK, transmission of HCV is predominantly through injection
drug use.1 Therefore, those most affected by HCV infection arepersons in socially excluded groups including people who inject
drugs (PWID). PWIDs are amongst the most stigmatised populations
and find it difficult to access healthcare due to services which dis-
criminate against them or don’t meet their specialised needs. This
makes diagnosis, referral and treatment challenging for them and
those providing services.
In patients with progressive hepatitis, approximately 10-20% of
patients will develop cirrhosis within 20-30 years, and once cirrhosis
develops there is a 1−5% annual risk of HCC and a 3−6% annual risk
of hepatic decompensation [1]. When determining1 the rate of dis-
ease progression, factors that increase fibrogenesis are alcohol con-
sumption, advancing age at infection (>40years at time of infection),
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and BMI >25 [2,4,5].
Since the common cause of HCV transmission in the UK is injec-
tion drug use, younger infected individuals are less likely to have sig-
nificant liver fibrosis due to the inherent lag in fibrogenesis
development. By extrapolation, those under 35 should not have sig-
nificant liver fibrosis given the short duration from time of infection
acquisition. This rationale is dependent on the absence of additional
hepatic insults. Within the developed world, both alcohol and meta-
bolic liver disease are important co-factor disease which should be
considered. Alcohol consumption appears to be a potent inducer of
fibrosis in those with HCV, particularly when drinking to hazardous
quantities i.e. >40g/day, with a significant risk of cirrhosis [6].
HCV treatment pathways may be considered as a cascade of care,
from diagnosis through to treatment endpoints [4]. The cascade of
care maps how infected persons move along a treatment pathway
from diagnosis, to engagement in care, treatment and finally, cure.
Intrinsic within these cascades are further steps such as referral to
HCV care, pre-treatment assessment, treatment monitoring and
acquisition of blood samples to confirm sustained viral response.
Each of these points represents a potential step at which a patient
may disconnect from services [7].
Worryingly, within these pathways a significant proportion of
patients often fail to even initiate therapy. Previous research by our-
selves, and others has shown that simplifying the treatment pathways
can be beneficial in engaging and retaining people in care [8−10].
Absolute consensus surrounding pre-treatment investigations is lack-
ing and there are several steps undertaken prior to commencement of
treatment. Guidelines recommend baseline liver fibrosis/cirrhosis
assessment but the absolutes of these vary significantly [11−13].
Baseline liver biochemistry is almost universally undertaken com-
prising of; ALT, AST, GGT, alkaline phosphatase, bilirubin, INR, albu-
min, gamma-globulins and full blood counts [5]. Some aspects of the
care cascade and pre-treatment assessment is a hangover from when
interferon containing regimes were the mainstay of treatment. Using
current technology, it is possible to make an HCV diagnosis using cap-
illary blood, obviating the need for venepuncture which may be chal-
lenging in those most likely to be infected with HCV [14]. However,
current strategies for fibrosis staging necessitates venepuncture or an
alternative imaging modality, which creates another step in the cas-
cade of care.
Given the changing treatment landscape of HCV with the intro-
duction of direct acting antivirals including pan-genotypic regimes
and reduced treatment durations there is an opportunity to re-evalu-
ate the steps in our care cascades and remove defunct steps. Thus, by
removing the barrier of fibrosis assessment at point of diagnosis the
expectation would be that increased engagement with treatment
strategies would ensue. Such evolution would be most welcome in
primary care, where, recent work by Whiteley [15] identified a prin-
ciple concern within primary-care based HCV treatment pathways
related to fibrosis assessment. Therefore, clear strategies obviating
this risk are necessary.
The simplification of the care pathway is expected to lead to
increased flow through the cascade of care, increasing individual
health benefits and reducing the pool of infectious people as vectors
of onward transmission. Several modelling studies have shown that
increased HCV treatment among PWID will reduce prevalence and
onward transmission, especially when combined with opioid substi-
tution therapy and high coverage of needle and syringe programmes
which has been subject to a Cochrane review [16]. Successful eradica-
tion programmes are dependent on a multifaceted approach to this
cohort of patients.
We sought to validate the hypothesis that patients who are aged
35 and under; and do not have additional risk factors for liver disease
would not have significant fibrosis and do not routinely require fibro-
sis assessment as part of their treatment strategy. Therefore, it would2
be possible to treat patients in this category immediately after con-
firming the diagnosis of chronic HCV infection.
2. Methods
The Tayside HCV clinical database records those patients diag-
nosed with HCV within NHS Tayside which covers; Dundee, Perth
and Kinross, North Fife and Angus (circa »450,000 catchment popu-
lation) from 1998. Fig. 1 outlines the process by which the cohort
was determined and subsequently analysed.
A retrospective analysis of the Tayside Hepatitis C dataset was
performed with collation of relevant demographics including age,
gender, and baseline transient elastography (TE) measurements for
those patients to age 45 (see Table 1), spanning from years 2009-
2018. Patients were age-stratified according to 4 categories,
≤30 years, 31-35, 36-40, and 41-45 years old and were treatment
naïve at time of assessment.
In determining the transient elastography measurement, all
patients underwent a Fibroscan  (Echosens, Paris, France) in the
supine position, having been fasted for > 4hours. Only the M probe
was used for LS measurement, with at least 10 validated measure-
ments with an interquartile range of ≤30% and a success rate of >70%
were included. No patients in the cohort were excluded on this basis
as all had reproducible results.
While the reproducibility of transient elastography and equiva-
lent METAVIR fibrosis stages has been demonstrated by previous
studies, variable cut-off values for each stage of fibrosis have been
proposed [12,13]. In this study the following classifications of fibrosis
were utilised: F0-1: <7, F2: 7-8.9, F3: 9-11.9 and F4: ≥12 kPa. Previ-
ous validation of transient elastography (TE) in HCV has suggested
that a cut off of less than 12 kPa excludes significant fibrosis [17].
FIB4 and APRI were assessed using validated cut-off scores to
determine the presence of fibrosis (within maximum 90 days of Tran-
sient Elastography measurements). Validated low (with high sensi-
tivity) and high (with high specificity) cut-off values used by WHO
for detection of fibrosis were 0.5 and 1.5 for APRI and 1.45 and 3.25
for FIB4. A value above the high cut-off suggests a high probability of
advanced fibrosis and below the lower cut-off interval intimating a
low probability of advanced fibrosis. Overall, for those above the rela-
tive cut-off values, we assessed for confounding risk factors; particu-
larly that of hazardous alcohol ingestion, NAFLD (features of
metabolic syndrome, significant radiological steatosis or histology
where available) and co-infection with other hepatotropic infections.
Elastography results are presented descriptively with mean and
relevant ranges. In determining age-related fibrosis association, we
used single factor ANOVA. All relevant calculations and statistics




Using the Tayside Hepatitis C database, there were a total of 719
patients who had been tested positive for HCV and undergone TE. The
TE results were taken prior to treatment. Initially, we screened patients
below the age of 45 and stratified them by age across 5-year intervals.
Of a total 719 patients with HCV, 471 of them were below the age of
45 (see Fig. 1). This cohort was the subject of the investigation.
The numbers and distribution between the subgroups of the
cohort are described in Table 1. Subgroup analysis demonstrated that
98% of patients below the age of 30 had a Fibroscan score less than
9kPa, with no patients having elastography >12kPa. Within the
cohort aged between 31-35 years; 15 patients (11.7%) had Fibroscan
results above 9kPa; with only 10 (8%) patients of these patients had
transient elastography >12kPa. Examination of these individuals risk
Table 1
Overview of Transient Elastography results across 5-year age intervals.
Age Range Total (n=) (M/F) Transient Elastography
(Mean; Range)
TE <9kPa 9-12kPa >12kPa
≤30 Years 139 (89/50) 5.45 (3.2-10.6) 136 3 0
31-35 128 (87/41) 5.9 (2.1-75.0) 113 5 10
36-40 104 (79/25) 6.06 (3.3-34.3) 86 10 8
41-45 96 (74/22) 6.1 (3.2-55.2) 78 5 13
Fig. 1. Flow diagram of individual groups within HCV Cohort in NHS Tayside.
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ardous alcohol consumption, and 3 further patients with risk factors
for NAFLD.
Further, 5 persons within the >12kPa subgroup had a history of
hazardous alcohol consumption. Finally, there are 5 persons (1.8%) of
the total 267 cohort ≤35 (or 3.9% of those 31-35 years) with signifi-
cant fibrosis in absence of additional hepatic risk factor ≤35 years
old. On an individual basis, only 2 of these 5 individuals had a tran-
sient elastography measurement >18kPa.
For completeness, we assessed those persons up to 45 years old.
Single factor ANOVA assessment across the groups (following exclu-
sion of those with significant additional fibrosis factors) demon-
strates clear age-related elastography increments (F = 7.988457,
p = 3.36E-05).3.2. Biochemical fibrosis scores
Separately, as an additional insight, we looked to determine the
utility of biochemical fibrosis markers commonly utilised in HCV
assessment in our cohort of individuals who had sequential transient3
elastography. The distribution of these scores is demonstrated in
Fig. 2.
Within the original cohort of patients with HCV under the age of
35 (n=267); there were 134 patients who did not have bloods per-
formed within the required timeframe or had an incomplete dataset.
Of the remaining 133 patients with complete data; 127 patients
had an APRI score of under 1.5 (95.5%) and 86 patients had a score
under 0.5 (64.7%). 131 patients had a FIB4 score of under 3.25 (98.5%)
and 125 patients had a FIB4 score of under 1.45 (94%).
Of the 41 patients with an APRI between 0.5 and 1.5, 4 had a FIB4
score over 1.45. Of the 6 patients with an APRI score over 1.5, 3 had a
FIB4 score over 1.45 (50%). A single patient had both an APRI over 1.5
and FIB4 over 3.25; however, they had TE under 9kPa. Further, 7
patients had both a FIB4 over 1.45 and APRI over 0.5 and therefore
would require further assessment with elastography. These 7 patients
subsequently all had TE of less than 9kPa, as demonstrated in Fig. 3.
4. Discussion
Given the challenge set by the WHO eradication targets, novel
approaches in the identification and treatment of HCV are
Fig. 3. Flowchart of FIB4 and APRI results.
Fig. 2. Distribution of FIB 4 and APRI Scores across cohorts.
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poorly served by fragmented, complex care systems which impacts
significantly on engagement and successful treatment. One aspect of
improving compliance is to reduce the requisite steps to access and
initiate treatment from time of diagnosis, minimizing patient attend-
ances across multiple locations and timepoints [7].
Given the advent of capillary blood for HCV diagnosis, venepunc-
ture is now relatively unnecessary, other than for staging of disease.
While routinely utilised in clinical practice, biochemical fibrosis
scores have clear limitations. APRI and FIB4 have previously been
shown to provide reliable, non-invasive fibrosis scoring in those with
hepatitis C, particularly when elastography is not available. Our
results show that of 133 patients under 35 years old with HCV and no
other co-factors, 7 would have required further fibrosis assessment
following biochemical scoring. These 7 patients all had a TE scores
excluding significant fibrosis. TE represents an alternative to blood-
based fibrosis assessment; however, there is little merit in offering
both methods.
Overall, these results support the hypothesis that; patients with
chronic HCV less than 35 years old in the absence of co-infectivity
with hepatotropic viruses, hazardous alcohol consumption or other
liver insult have a negligible risk of significant fibrosis. The chances of4
missing someone with significant fibrosis is less than 1 in 20, which
is markedly lower than the risk of losing someone from a treatment
pathway through the addition of requisitel steps, thereby losing any
apparent benefit of treatment. No one within the cohort had suffi-
ciently injurious liver fibrosis to impact on choice of treatment, given
the safety of DAA regimes even in patients with compensated cirrho-
sis [18]. Furthermore, the relative benefit of DAA treatment in reduc-
ing all-cause mortality and hepatocellular carcinoma development in
chronic HCV represents a clear benefit: risk compromise in such an
approach to treatment [18]. In extending our assessments to include
those patients up to age 45 years, our data supports previous findings
that prolonged duration of infection contributes to temporally medi-
ated fibrogenesis in HCV infection.
Therefore, from our results we suggest a modified approach to
community HCV treatment. This proposed pathway suggests that fol-
lowing positive screening for anti-HCV antibody; confirmatory test-
ing and concurrent history is acquired by a healthcare professional.
This screening would include additional hepatotoxic risk factors
including alcohol and metabolic features. This would then allow
immediate dispensing arrangements for DAA. Of course, this
approach can be modified somewhat to allow for local/national
agreements, healthcare infrastructure and relative logistics.
This approach has clear perceived benefit, whereby, the immedi-
ate offering of DAAs should improve uptake and completion of treat-
ment given the emerging real-world data. Radley and colleagues [19]
demonstrated how incremental SVR could be achieved through such
reconciliation of complex pathways. This work identified that those
patients randomized to traditional medical care model were signifi-
cantly less likely to achieve SVR, with progressive drop out at each
step within the cascade of care. Depending of the intervention,
observed dropout was between 5-59%.
Clearly whilst the numbers demonstrate an increase in overall
numbers with increasing fibrosis propensity, most patients do not
have advanced disease.
Clearly our study has some limitations in its design, particularly as
it is retrospective and there are several individuals whose medical
records are incomplete. It is also accepted that we use TE as an de-
facto gold-standard for fibrosis assessment, it is however, helpful in
the context of those who have had both biochemical and TE per-
formed, given the utility of TE in HCV fibrosis assessment is well
described. We do recognise the limitations of transient elastography,
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particularly operator dependence and reproducibility. In those
patients without overt risk factors clearly documented, we looked to
include them in the statistical assessment, therefore we may indeed
underestimate co-factors in these individuals.
Overall, however, the data here represents real-life information in
a challenging area of practice, albeit, in one where real change is pos-
sible. A similar smaller study was performed in a needle-exchange
centre in Stockholm [20], with similar outcomes, however, it would
be worthwhile validating these findings across other populations in
other geographical regions.5. Conclusion
Currently, standard recommendations advocate liver fibrosis
assessment prior to initiation of antiretroviral therapy. We demon-
strate that individuals who are mono-infected with HCV, of the age
≤35 years old and do not have additional hepatic insult have a negli-
gible likelihood of having significant fibrosis. Therefore, these
patients do not need fibrosis staging and should rather proceed direct
to treatment.
Simplification of treatment stratagems as proposed herein should
readily facilitate and improve treatment engagement, and conse-
quent completion rates through minimising steps in the HCV cascade
of care. It is through novel, innovative approaches to age-old chal-
lenges that the realisation of global HCV elimination by 2030 may be
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